166 related articles for article (PubMed ID: 33448539)
1. Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?
Koch MW; Mostert J; Repovic P; Bowen JD; Uitdehaag B; Cutter G
Eur J Neurol; 2021 Jun; 28(6):2115-2120. PubMed ID: 33448539
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing-Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset.
Castrogiovanni N; Mostert J; Repovic P; Bowen JD; Uitdehaag BMJ; Strijbis EMM; Cutter GR; Koch MW
Neurology; 2023 Jul; 101(1):e1-e11. PubMed ID: 37072219
[TBL] [Abstract][Full Text] [Related]
3. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
Benedict RHB; Tomic D; Cree BA; Fox R; Giovannoni G; Bar-Or A; Gold R; Vermersch P; Pohlmann H; Wright I; Karlsson G; Dahlke F; Wolf C; Kappos L
Neurology; 2021 Jan; 96(3):e376-e386. PubMed ID: 33328324
[TBL] [Abstract][Full Text] [Related]
4. A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity.
López-Góngora M; Querol L; Escartín A
BMC Neurol; 2015 Mar; 15():40. PubMed ID: 25886168
[TBL] [Abstract][Full Text] [Related]
5. The symbol digit modalities test and the paced auditory serial addition test involve more than processing speed.
Berrigan LI; LeFevre JA; Rees LM; Berard JA; Francis A; Freedman MS; Walker LAS
Mult Scler Relat Disord; 2022 Dec; 68():104229. PubMed ID: 36279599
[TBL] [Abstract][Full Text] [Related]
6. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.
Drake AS; Weinstock-Guttman B; Morrow SA; Hojnacki D; Munschauer FE; Benedict RH
Mult Scler; 2010 Feb; 16(2):228-37. PubMed ID: 20028710
[TBL] [Abstract][Full Text] [Related]
7. Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis.
Sonder JM; Burggraaff J; Knol DL; Polman CH; Uitdehaag BM
Mult Scler; 2014 Apr; 20(4):481-8. PubMed ID: 24019305
[TBL] [Abstract][Full Text] [Related]
8. Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis.
Papadopoulou A; Müller-Lenke N; Naegelin Y; Kalt G; Bendfeldt K; Kuster P; Stoecklin M; Gass A; Sprenger T; Radue EW; Kappos L; Penner IK
Mult Scler; 2013 Sep; 19(10):1290-6. PubMed ID: 23459568
[TBL] [Abstract][Full Text] [Related]
9. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.
DeLuca J; Schippling S; Montalban X; Kappos L; Cree BAC; Comi G; Arnold DL; Hartung HP; Sheffield JK; Liu H; Silva D; Cohen JA
Mult Scler Relat Disord; 2021 Feb; 48():102673. PubMed ID: 33454584
[TBL] [Abstract][Full Text] [Related]
10. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.
Brochet B; Deloire MS; Bonnet M; Salort-Campana E; Ouallet JC; Petry KG; Dousset V
Mult Scler; 2008 Nov; 14(9):1242-9. PubMed ID: 18653737
[TBL] [Abstract][Full Text] [Related]
11. MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis.
Koch MW; Mostert J; Repovic P; Bowen JD; Strijbis E; Uitdehaag B; Cutter G
Mult Scler; 2022 Apr; 28(4):561-572. PubMed ID: 34304609
[TBL] [Abstract][Full Text] [Related]
12. Symbol Digit Modalities Test: Greek Normative Data for the Oral and Written Version and Discriminative Validity in Patients with Multiple Sclerosis.
Messinis L; Bakirtzis C; Kosmidis MH; Economou A; Nasios G; Anyfantis E; Konitsiotis S; Ntoskou A; Peristeri E; Dardiotis E; Grigoriadis N; Gourzis P; Papathanasopoulos P
Arch Clin Neuropsychol; 2021 Jan; 36(1):117-125. PubMed ID: 32385488
[TBL] [Abstract][Full Text] [Related]
13. Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.
Strober L; DeLuca J; Benedict RH; Jacobs A; Cohen JA; Chiaravalloti N; Hudson LD; Rudick RA; LaRocca NG;
Mult Scler; 2019 Nov; 25(13):1781-1790. PubMed ID: 30334474
[TBL] [Abstract][Full Text] [Related]
14. Symbol Digit Modalities Test in progressive multiple sclerosis.
Gajewski B; Karlińska I; Stasiołek M
Neurol Neurochir Pol; 2024; 58(3):221-232. PubMed ID: 38512126
[TBL] [Abstract][Full Text] [Related]
15. Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis.
Waldman AT; Chahin S; Lavery AM; Liu G; Banwell BL; Liu GT; Balcer LJ
Mult Scler Relat Disord; 2016 Nov; 10():73-78. PubMed ID: 27919503
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients.
Niccolai C; Portaccio E; Goretti B; Hakiki B; Giannini M; Pastò L; Righini I; Falautano M; Minacapelli E; Martinelli V; Incerti C; Nocentini U; Fenu G; Cocco E; Marrosu MG; Garofalo E; Ambra FI; Maddestra M; Consalvo M; Viterbo RG; Trojano M; Losignore NA; Zimatore GB; Pietrolongo E; Lugaresi A; Pippolo L; Roscio M; Ghezzi A; Castellano D; Stecchi S; Amato MP
BMC Neurol; 2015 Oct; 15():204. PubMed ID: 26472052
[TBL] [Abstract][Full Text] [Related]
17. [Information processing speed and influential factors in multiple sclerosis].
Zhang ML; Xu EH; Dong HQ; Zhang JW
Zhonghua Yi Xue Za Zhi; 2016 Apr; 96(15):1173-7. PubMed ID: 27117362
[TBL] [Abstract][Full Text] [Related]
18. Cognitive impairment and decline in different MS subtypes.
Huijbregts SC; Kalkers NF; de Sonneville LM; de Groot V; Polman CH
J Neurol Sci; 2006 Jun; 245(1-2):187-94. PubMed ID: 16643951
[TBL] [Abstract][Full Text] [Related]
19. Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI.
Wen J; Yablonskiy DA; Luo J; Lancia S; Hildebolt C; Cross AH
Neuroimage Clin; 2015; 9():164-75. PubMed ID: 27330979
[TBL] [Abstract][Full Text] [Related]
20. Symbol digit modalities test predicts decline of off-road driving ability in Japanese patients with multiple sclerosis.
Maeta M; Mizuno M; Okubo S; Ogasawara M; Terauchi T; Suzuki M; Akasaka H; Sato Y; Ohi K; Maeda T
Mult Scler Relat Disord; 2022 Dec; 68():104150. PubMed ID: 36055114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
